Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flinn

Showing results (841-850 of 1,038) with videos related to

Pageof 104
Sort By:
Blood|March 17, 2012
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaShaji Kumar, Ian Flinn, Paul G Richardson, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
Novel Insights into Post-Myocardial Infarction Cardiac Remodeling through Algorithmic Detection of Cell-Type Composition ShiftsBrian Gural, Logan Kirkland, Abbey Hockett, et al.
The Lancet. Oncology|July 22, 2014
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b studyAnas Younes, Catherine Thieblemont, Franck Morschhauser, et al.
Haematologica|January 13, 2022
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.
Annals of Hematology|May 21, 2021
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE studyRichard Greil, Alessandra Tedeschi, Carol Moreno, et al.
Oncotarget|March 22, 2018
First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLLJohn C Byrd, Stephen Smith, Nina Wagner-Johnston, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 27, 2003
Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cellsCarol Ann Huff, Ephraim J Fuchs, Stephen J Noga, et al.
The Lancet. Oncology|August 23, 2011
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialHagop M Kantarjian, Andreas Hochhaus, Giuseppe Saglio, et al.
Blood Advances|May 7, 2025
Zanubrutinib is well tolerated and effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib: Updated resultsMazyar Shadman, John M Burke, Jennifer Cultrera, et al.
Health Security|February 20, 2019
Simulation of a Spontaneous Vaginal Delivery and Neonatal Resuscitation in a Biocontainment UnitBenjamin K Kogutt, Jeanne S Sheffield, Dianne Whyne, et al.
Pageof 104

Showing results (841-850 of 1,038) with videos related to

Sort By:
Pageof 104
Blood|March 17, 2012
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaShaji Kumar, Ian Flinn, Paul G Richardson, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
Novel Insights into Post-Myocardial Infarction Cardiac Remodeling through Algorithmic Detection of Cell-Type Composition ShiftsBrian Gural, Logan Kirkland, Abbey Hockett, et al.
The Lancet. Oncology|July 22, 2014
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b studyAnas Younes, Catherine Thieblemont, Franck Morschhauser, et al.
Haematologica|January 13, 2022
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.
Annals of Hematology|May 21, 2021
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE studyRichard Greil, Alessandra Tedeschi, Carol Moreno, et al.
Oncotarget|March 22, 2018
First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLLJohn C Byrd, Stephen Smith, Nina Wagner-Johnston, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 27, 2003
Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cellsCarol Ann Huff, Ephraim J Fuchs, Stephen J Noga, et al.
The Lancet. Oncology|August 23, 2011
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialHagop M Kantarjian, Andreas Hochhaus, Giuseppe Saglio, et al.
Blood Advances|May 7, 2025
Zanubrutinib is well tolerated and effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib: Updated resultsMazyar Shadman, John M Burke, Jennifer Cultrera, et al.
Health Security|February 20, 2019
Simulation of a Spontaneous Vaginal Delivery and Neonatal Resuscitation in a Biocontainment UnitBenjamin K Kogutt, Jeanne S Sheffield, Dianne Whyne, et al.
Pageof 104